Atypical Antipsychotics

PreclinicalSmall molecule

Atypical Antipsychotics is one of 114 small molecule programs targeting Metabolic Syndrome. It is currently in Preclinical.

Indications

Total Trials

Active Trials

113

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metabolic SyndromeActive, not recruiting

StrokeActive, not recruiting

SchizophreniaActive, not recruiting

Metabolic SyndromePreclinical

Active, not recruiting

StrokePreclinical

Active, not recruiting

SchizophreniaPreclinical

Active, not recruiting

Competition

Competitive Landscape

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Celexa

AbbVie

Preclinical

4 2

Ozempic

Novo Nordisk

Preclinical

1 3

Resotran

Takeda

Preclinical

1 4

Inapsine

Alnylam Pharmaceuticals

Preclinical

1 5

Zocor

OOrganon and Co

Preclinical

6 6

Depakote

Ibrance

Lunesta

3 9

Luvox

SSolvay Pharmaceuticals

Preclinical

1 10

Catapres

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Antipsychotics2 trials

Clinical Registry of Patients Under Treatment With Atypical Antipsychotics

Completed·PPontifical Catholic University of Argentina··NCT02409823·665 enrolled

Antipsychotics and Risk of Hyperglycemic Emergencies

Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02582736·725,489 enrolled

Schizophrenia1 trial

The Paliperidone ER Observational Study of Economic, Functional, and Clinical Outcomes in Patients With Schizophrenia

Terminated· Johnson & Johnson logo

Johnson & Johnson··NCT00488891·43 enrolled

Metabolic Syndrome1 trial

Efficacy of Pediococcus Acidilactici as add-on to Antipsychotic Drugs on Metabolic Syndrome Disturbances in First-episode Psychosis and Schizophrenia Spectrum Disorders. A Double-blind Placebo-controlled Trial.

Active, not recruiting·MManuel Jesús Cuesta Zurita·N/A·NCT07371325·36 enrolled

Stroke1 trial

A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT04002700·1,234,412 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Atypical Antipsychotics. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Atypical Antipsychotics compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Atypical Antipsychotics. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Johnson & Johnson

Atypical Antipsychotics

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Antipsychotics2 trials

Schizophrenia1 trial

Metabolic Syndrome1 trial

Stroke1 trial

References

Drug Info

Quick Facts

Related News